Form 4: Fate Therapeutics Executive Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Cindy Tahl, Chief Legal & Compliance Officer and Secretary of Fate Therapeutics, sold shares to cover tax withholding obligations related to vesting RSUs.
Summary
- On January 10, 2025, Cindy Tahl, Chief Legal & Compliance Officer and Secretary of Fate Therapeutics, sold 5,654 shares of common stock.
- The sale was executed to cover tax withholding obligations related to the vesting of 4,504 shares of common stock underlying RSUs granted on January 20, 2021, and 8,325 shares of common stock underlying RSUs granted on January 25, 2022.
- The shares were sold at a weighted average price ranging from $1.53 to $1.62 per share, with the total shares beneficially owned after the transaction being 336,707.
- The sale was made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through 'sell to cover' transactions and does not represent discretionary trades by the Reporting Person.
Sentiment
Score: 6
Explanation: Neutral sentiment. The filing reflects a routine transaction to cover tax obligations, not indicative of a significant positive or negative outlook for the company.
Industry Context
This is a routine Form 4 filing, reflecting an insider's stock sale to cover tax obligations, a common practice among executives receiving equity compensation. It doesn't necessarily indicate a change in the executive's confidence in the company.
Comparison to Industry Standards
- Similar 'sell to cover' transactions are common among executives at publicly traded companies, including those in the biotechnology sector like Fate Therapeutics.
- Companies such as Juno Therapeutics (acquired by Celgene) and Kite Pharma (acquired by Gilead) have seen similar filings related to RSU vesting and tax obligations.
- The volume of shares sold is relatively small compared to the total shares outstanding, suggesting it's unlikely to have a significant impact on the stock price.
Stakeholder Impact
- The sale of shares could have a minor, temporary impact on the stock price, but is unlikely to significantly affect shareholders in the long term.
- Employees holding RSUs may experience similar tax obligations upon vesting.
Key Dates
| Date | Description |
|---|---|
| January 20, 2021 | Date of RSU grant underlying 4,504 shares of Common Stock. |
| January 25, 2022 | Date of RSU grant underlying 8,325 shares of Common Stock. |
| January 10, 2025 | Date of transaction: sale of 5,654 shares of common stock. |
| January 13, 2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.